Company Overview
Kairos Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies designed to overcome drug resistance and immune suppression in cancer patients. Our lead candidate, ENV105, is an antibody that targets CD105—a protein identified as a key driver of resistance to various cancer treatments. By inhibiting CD105 on cancer cell surfaces, ENV105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in Phase 2 clinical trials for prostate cancer and Phase 1 trials for lung cancer, addressing significant unmet medical needs.
Learn More